Evidence map›Paper›PMID 34830756›Full record

ArticleCancers2021

Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies.

Magdalena M Brune, Achim Rau, Mathis Overkamp, Tim Flaadt, Irina Bonzheim, Christian M Schürch, Birgit Federmann, Stefan Dirnhofer, Falko Fend, Alexandar Tzankov

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Magdalena M BruneInstitute of Medical Genetics and Pathology, University Hospital Basel, Schönbeinstrasse 40, CH-4031 Basel, Switzerland.
Achim RauInstitute of Pathology and Neuropathology, University Hospital Tübingen, 72076 Tübingen, Germany.ORCID 0000-0003-2497-7038
Mathis OverkampInstitute of Pathology and Neuropathology, University Hospital Tübingen, 72076 Tübingen, Germany.
Tim FlaadtInstitute of Pathology and Neuropathology, University Hospital Tübingen, 72076 Tübingen, Germany.
Irina BonzheimInstitute of Pathology and Neuropathology, University Hospital Tübingen, 72076 Tübingen, Germany.
Christian M SchürchInstitute of Pathology and Neuropathology, University Hospital Tübingen, 72076 Tübingen, Germany.ORCID 0000-0002-1792-1768
Birgit FedermannInstitute of Pathology and Neuropathology, University Hospital Tübingen, 72076 Tübingen, Germany.
Stefan DirnhoferInstitute of Medical Genetics and Pathology, University Hospital Basel, Schönbeinstrasse 40, CH-4031 Basel, Switzerland.
Falko FendInstitute of Pathology and Neuropathology, University Hospital Tübingen, 72076 Tübingen, Germany.
Alexandar TzankovInstitute of Medical Genetics and Pathology, University Hospital Basel, Schönbeinstrasse 40, CH-4031 Basel, Switzerland.ORCID 0000-0002-1100-3819
University Children's Hospital Tübingen · DEUniversity Hospital of Basel · CHUniversity of Bern · CH

Funding

Swiss Life Jubiläumsstiftung n.a.
6 · The paper itself

Abstract

Myeloproliferative neoplasms (MPN) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) both harbor the potential to undergo myelodysplastic progression or acceleration and can transform into blast-phase MPN or MDS/MPN, a form of secondary acute myeloid leukemia (AML). Although the initiating transforming events are yet to be determined, current concepts suggest a stepwise acquisition of (additional) somatic mutations-apart from the initial driver mutations-that trigger disease evolution. In this study we molecularly analyzed paired bone marrow samples of MPN and MDS/MPN patients with known progression and compared them to a control cohort of patients with stable disease course. Cases with progression displayed from the very beginning a higher number of mutations compared to stable ones, of which mutations in five (

Indexed as

genetic testingmutation analysismyelodysplastic/myeloproliferative neoplasmmyeloproliferative neoplasmrisk stratificationsecondary acute myeloid leukemia

Identifiers

PMID34830756
PMCPMC8615857
OpenAlexW3214403426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.